BRPI0009448B8 - kit para uso no tratamento de uma neoplasia em um mamífero - Google Patents

kit para uso no tratamento de uma neoplasia em um mamífero

Info

Publication number
BRPI0009448B8
BRPI0009448B8 BRPI0009448A BR0009448A BRPI0009448B8 BR PI0009448 B8 BRPI0009448 B8 BR PI0009448B8 BR PI0009448 A BRPI0009448 A BR PI0009448A BR 0009448 A BR0009448 A BR 0009448A BR PI0009448 B8 BRPI0009448 B8 BR PI0009448B8
Authority
BR
Brazil
Prior art keywords
treating
mol
neoplasm
mammal
kit
Prior art date
Application number
BRPI0009448A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0009448A (pt
BRPI0009448B1 (pt
Inventor
H Sarris Andreas
T R Burge Clive
Cabanillas Fernando
H Goldie James
David Mayer Lawrence
S Webb Murray
M Logan Patricia
Original Assignee
Univ Texas
Hana Biosciences Inc
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Hana Biosciences Inc, Inex Pharmaceuticals Corp filed Critical Univ Texas
Publication of BR0009448A publication Critical patent/BR0009448A/pt
Publication of BRPI0009448B1 publication Critical patent/BRPI0009448B1/pt
Publication of BRPI0009448B8 publication Critical patent/BRPI0009448B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0009448A 1999-04-01 2000-03-31 kit para uso no tratamento de uma neoplasia em um mamífero BRPI0009448B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12744499P 1999-04-01 1999-04-01
US13719499P 1999-06-02 1999-06-02
PCT/US2000/008669 WO2000059473A1 (en) 1999-04-01 2000-03-31 Compositions and methods for treating lymphoma

Publications (3)

Publication Number Publication Date
BR0009448A BR0009448A (pt) 2002-01-08
BRPI0009448B1 BRPI0009448B1 (pt) 2018-09-11
BRPI0009448B8 true BRPI0009448B8 (pt) 2021-05-25

Family

ID=26825635

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0009448A BRPI0009448B8 (pt) 1999-04-01 2000-03-31 kit para uso no tratamento de uma neoplasia em um mamífero

Country Status (13)

Country Link
EP (3) EP1985285A3 (https=)
JP (3) JP2002541088A (https=)
AT (1) ATE442839T1 (https=)
AU (1) AU777572B2 (https=)
BR (1) BRPI0009448B8 (https=)
CA (1) CA2366787C (https=)
CY (1) CY1109641T1 (https=)
DE (1) DE60042968D1 (https=)
DK (2) DK2266537T3 (https=)
ES (2) ES2524141T3 (https=)
IL (4) IL145720A0 (https=)
PT (1) PT1169021E (https=)
WO (1) WO2000059473A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
WO2000059473A1 (en) * 1999-04-01 2000-10-12 Inex Pharmaceuticals Corp. Compositions and methods for treating lymphoma
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
ATE440593T1 (de) * 2001-03-27 2009-09-15 Phares Pharm Res Nv Verfahren und zusammensetzung zur solubilisierung einer biologisch wirksamen verbindung mit geringer wasserlíslichkeit
CA2752124A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
FR2840203B1 (fr) * 2002-05-31 2004-08-27 Scherer Technologies Inc R P Composition pharmaceutique orale pour capsules molles contenant vinorelbine et methode de traitement
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
RU2252764C2 (ru) * 2003-03-04 2005-05-27 Российский научный центр рентгенорадиологии МЗ РФ Способ комплексного лечения лимфогранулематоза
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005011698A1 (en) * 2003-07-28 2005-02-10 Inex Pharmaceuticals Corporation Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
WO2006005477A1 (en) * 2004-07-09 2006-01-19 Schering Ag Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma
JP5199666B2 (ja) * 2004-08-10 2013-05-15 タロン セラピューティクス インコーポレイテッド 白血病を治療するための組成物および方法
HRP20160625T1 (hr) * 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
WO2010047714A1 (en) * 2008-10-24 2010-04-29 Gloucester Pharmaceuticals Cancer therapy
MX2015005992A (es) 2012-11-20 2016-03-07 Spectrum Pharmaceuticals Inc Metodo mejorado para la preparacion de la vincristina liposomal encapsulada para el uso terapeutico.
WO2014116866A1 (en) * 2013-01-24 2014-07-31 Memorial Sloan Kettering Cancer Center Method for diagnosing or treating tumors using sphingomyelin containing liposomes
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
TWI678213B (zh) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
SI26542A (sl) 2023-09-12 2025-03-31 Univerza V Ljubljani Nove liposomske formulacije in postopek za njihovo pripravo

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
GB9304745D0 (en) * 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
WO2000059473A1 (en) * 1999-04-01 2000-10-12 Inex Pharmaceuticals Corp. Compositions and methods for treating lymphoma

Also Published As

Publication number Publication date
CA2366787C (en) 2013-03-12
JP2012158602A (ja) 2012-08-23
CY1109641T1 (el) 2014-08-13
AU4060600A (en) 2000-10-23
IL145720A (en) 2011-05-31
CA2366787A1 (en) 2000-10-12
IL212390A0 (en) 2011-06-30
IL212389A0 (en) 2011-06-30
AU777572B2 (en) 2004-10-21
ES2524141T3 (es) 2014-12-04
DK1169021T3 (da) 2010-01-11
EP1169021A1 (en) 2002-01-09
JP5981214B2 (ja) 2016-08-31
JP2002541088A (ja) 2002-12-03
BR0009448A (pt) 2002-01-08
IL212390A (en) 2014-08-31
BRPI0009448B1 (pt) 2018-09-11
IL145720A0 (en) 2002-07-25
EP2266537A2 (en) 2010-12-29
PT1169021E (pt) 2009-11-18
JP2015071631A (ja) 2015-04-16
EP1985285A2 (en) 2008-10-29
DE60042968D1 (de) 2009-10-29
HK1152246A1 (en) 2012-02-24
EP2266537B1 (en) 2014-09-03
EP1985285A3 (en) 2009-08-12
ATE442839T1 (de) 2009-10-15
ES2333400T3 (es) 2010-02-22
EP1169021B1 (en) 2009-09-16
WO2000059473A1 (en) 2000-10-12
EP2266537A3 (en) 2012-02-22
DK2266537T3 (en) 2014-12-15
IL212389A (en) 2015-07-30

Similar Documents

Publication Publication Date Title
BRPI0009448B8 (pt) kit para uso no tratamento de uma neoplasia em um mamífero
LV11430A (lv) 2-Piridilmetilenpoliazamakrociklofosfonskabes to kompleksi un atvasinajumi izmantosanai par kontrastvielam
SE8502573D0 (sv) Fluorescent lanthanide chelates useful as labels of physiologically active materials
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
GB9406857D0 (en) Improvements in or relating to organic compounds
CA2367505A1 (en) Coloring ceramics by way of ionic or complex-containing solutions
BR9908273A (pt) Formulações
TR200102800T2 (tr) Yeni bileşikler.
TR200000576T1 (tr) Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
IL132107A0 (en) Substituted phenyl derivatives their preparation and use
LV11429A (lv) Triciklopoliazamakrociklofosfonskabes to kompleksi un atvasinajumi izmantosanai par kontrastvielam
DE3773237D1 (de) Einen makrozyklischen koordinat und einen antikoerper enthaltende konjugatverbindung.
ATE320457T1 (de) Polyurethanlösungen mit alkoxysilanstruktureinheiten
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
TR199802559A2 (xx) �kame edilmi� poliaminokarboksilik makro devirli metal kenetlenme
AU5727899A (en) Diaminocyclobutene-3,4-dione derivatives, their preparation and use
TR200101493T2 (tr) Eletriptan hidrobromid monohidrat
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
BR9814519A (pt) Uso de compostos quìmicos promotores de oxidação na oxidação de polìmero contendo configuração álcool tipo galactose oxidável
TR200001715T2 (tr) Potasyum kanalı açıcıları.
WO2001047477A3 (de) Mittel zum färben von keratinhaltigen fasern
TR199901232T2 (xx) Canl� organizmalara peptitli farmakonlar�n verilmesi i�in lokal terkip.
DE69807200D1 (de) Inklusionskomplexe in waessriger loesung
IL127930A0 (en) Verapamil as a medicament for the treatment of angina
ATE231838T1 (de) N,n'-diacylthiocystine

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: INEX PHARMACEUTICALS CORPORATION (CA), BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US)

B25A Requested transfer of rights approved

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (

Free format text: TRANSFERIDO DE: INEX PHARMACEUTICALS CORPORATION

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13 E 10 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/03/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 31/03/2020

B15V Prolongation of time limit allowed